Search By Tags
Peter C. Farrell, PhD, DSc, AM
Founder And Chairman Of The Board, ResMed
Mauro Mileni, CEO: Mauro is the founder of Abilita Bio, Inc. and inventor
of the EMP ™ technology it was formed around. He has 18 years of experience working with membrane proteins and GPCRs and has authored eighteen peer-reviewed scientific articles. He received his PhD from the Max Planck Institute under Nobel laureate Prof. Hartmut Michel, carried out his postdoctoral studies in the laboratory of Prof. Raymond Stevens at The Scripps Research Institute (TSRI), widely regarded as the world’s top lab for GPCR structural studies, worked as a scientist in the Structural Biology group at Receptos, Inc. and has consulted for Lilly & Company.
Transforming the Field of Membrane Protein Drug Discovery
By: Mauro Mileni
What is microbiome doing and can we change what it does?
Dr. Amir Zarrinpar, MD, PhD, Assistant Professor, Division of Gastroenterology, University of California, San Diego
Dr. Jiwu Wang received his undergraduate degree in Biochemistry from Peking University in1989 and Ph.D. in molecular biology from USC in1994. He worked in the RNA-related fields in graduate school and as a postdoc at UCSD. After his postdoc training with an NIH postdoc fellowship for 3 years, he founded Allele Biotechnology and Pharmaceuticals. Dr. Wang has major publications on stem cell biology and manufacturing, among his other scientific achievements.
Allele is pioneering mRNA combinations to create then derive autologous iPSCs into pancreatic beta cells for diabetes, oligodendrocytes for spinal injury, and nano antibody-based CAR-T cell therapy plans. Several nano antibody drug candidates developed at Allele against cancer or inflammation targets are at the in vivo efficacy stage. He also founded the non-profit Scintillon Institute and serves as its president and professor. The institute has about 10 faculty memebers working on cytometry, translational research in various disease areas, particularly in neural degenerative diseases.Furthermore, iPSC-derived various tissue cells will be used for new drug screening on a industry level and pre-treatment suitability testing on a personal level. Allele is working with the FDA to explore a modern pathway that is more suited for evidence-based therapies that focuses on one person at a time while still keeping production and operation under current Good Manufacturing Practice (cGMP).